You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Corcept Therapeutics plans $100M share buyback program
Global M&A Infographic Q1 2021
Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge
COVID-19 Impact & Recovery: Private Equity
COVID-19 Impact & Recovery: Corporates
Corcept Therapeutics Inc. said its board approved the repurchase of up to $100 million of the company's common stock.
The Menlo Park, Calif.-based pharmaceutical company said the share buyback program will remain in effect until June 30, 2019, unless terminated earlier.
Corcept added that the timing and amount of any repurchases will be based on market conditions, stock price and other factors.